Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Based in Rehovot.
Kamada: net income sharply up (+28.5%), sales up (+12.1%), cash flow sharply up (+110.0%).
- Net income sharply upFirst nine months 2026
Net income: $21M, vs. $17M a year earlier, i.e. +28.5%.
- Sales upFirst nine months 2026
Revenue: $152M, vs. $136M a year earlier, i.e. +12.1%.
- Cash flow sharply upFirst nine months 2026
Operating cash flow: $38M, vs. $18M a year earlier, i.e. +110.0%.
- Operating income sharply upFirst nine months 2026
Operating income: $27M, vs. $23M a year earlier, i.e. +18.3%.
What the market pays, vs. the sector
This company's valuation multiples history is being built day by day from now on.
P/E calculated on net income (trailing 12 months: last fiscal year + 2026 year-to-date − same period a year earlier). Sector median: companies in the — group tracked here. Prices: Yahoo Finance; market cap cross-checked with the Tel Aviv Stock Exchange for Israeli stocks. These ratios describe a price, not a value: none of them says whether the share is expensive or cheap.
Dividend per share, over 5 years
Total dividends per share paid each calendar year (1 year(s) out of 5 with a payment). Source: Yahoo Finance. The current year is not complete.
Follow earnings · WhatsApp group TA-125Details ▾
Every report from a TA-125 company, analyzed the same day: key figures and year-on-year change, analysis in brief, share price reaction. One daily summary during earnings season.
Join the TA-125 groupDetailed figures and history
Financial summary
| 9 months 2026 | 9 months 2025 | FY 2025 | |
|---|---|---|---|
| Total assets | 383 | 377 | 379 |
| Current assets | 200 | 193 | 193 |
| Non-current assets | 182 | 184 | 186 |
| Equity | 268 | 265 | 269 |
| of which minority interests | 0 | 0 | 0 |
| Current liabilities | 48 | 48 | 47 |
| Non-current liabilities | 66 | 64 | 62 |
| Revenue | 152 | 136 | 180 |
| Gross profit | 65 | 59 | 76 |
| Operating income | 27 | 23 | 26 |
| Pre-tax income | 25 | 19 | 23 |
| Net income | 21 | 17 | 20 |
| Net income (attributable to shareholders) | 21 | 17 | 20 |
| Dividends paid | 0 | −12 | −12 |
| Operating cash flow | 38 | 18 | 25 |
In millions of dollars. The "H1" columns cover the first six months of the year.
Calculated from these figures
| 9 months 2026 | 9 months 2025 | FY 2025 | |
|---|---|---|---|
| Gross margin | 42.7% | 43.8% | 42.3% |
| Operating margin | 17.6% | 16.7% | 14.5% |
| Net margin | 14.1% | 12.3% | 11.2% |
| Current ratio (current assets / current liabilities) | 4,2 x | 4,0 x | 4,1 x |
| Equity / total assets | 70.1% | 70.3% | 71.0% |
The 5-year history, charts and cross-check models are coming for companies listed only in Tel Aviv: each new filing on Maya is kept and enriches the page.
Company overview
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Source: official company profile (Yahoo Finance), summary. Website: www.kamada.com
- Maya, Tel Aviv Stock Exchange: company page and reports